Published in Nat Rev Clin Oncol on August 12, 2014
AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00305656
Improved Therapy Response Assessment in Metastatic Brain Tumors (TREATMENT) | NCT03458455
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A (2016) 0.86
The Contribution of Angiogenesis to the Process of Metastasis. Cancer J (2015) 0.80
Brain Vascular Imaging Techniques. Int J Mol Sci (2016) 0.75
MR Vascular Fingerprinting in Stroke and Brain Tumors Models. Sci Rep (2016) 0.75
Biomimetic on-a-chip platforms for studying cancer metastasis. Curr Opin Chem Eng (2015) 0.75
Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model. BMC Cancer (2016) 0.75
Noninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Ductal Adenocarcinoma. Transl Oncol (2016) 0.75
Assessment of bevacizumab resistance increased by expression of BCAT1 in IDH1 wild-type glioblastoma: application of DSC perfusion MR imaging. Oncotarget (2016) 0.75
Vasculature-specific MRI reveals differential anti-angiogenic effects of a biomimetic peptide in an orthotopic breast cancer model. Angiogenesis (2014) 0.75
Imaging Tumor Vascularity and Response to Anti-Angiogenic Therapy Using Gaussia Luciferase. Sci Rep (2016) 0.75
Magnetic resonance fingerprinting based on realistic vasculature in mice. Neuroimage (2016) 0.75
A theoretical framework for determining cerebral vascular function and heterogeneity from dynamic susceptibility contrast MRI. J Cereb Blood Flow Metab (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol (1990) 18.71
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci U S A (1990) 17.55
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. Chem Rev (1999) 12.52
Angiogenesis as a therapeutic target. Nature (2005) 11.89
Molecular regulation of vessel maturation. Nat Med (2003) 11.74
Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov (2007) 11.46
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med (2001) 10.37
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med (2014) 9.09
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer (2008) 7.86
Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol (2006) 7.19
Targeting hypoxia in cancer therapy. Nat Rev Cancer (2011) 7.10
High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med (1996) 6.90
Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest (1999) 6.32
On the theory of the indicator-dilution method for measurement of blood flow and volume. J Appl Physiol (1954) 5.57
Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med (2009) 5.41
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
Perfusion imaging with NMR contrast agents. Magn Reson Med (1990) 5.01
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol (2012) 4.84
MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med (1995) 4.72
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer (2008) 4.71
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol (2008) 4.66
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 4.23
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res (1994) 3.84
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol (2013) 3.81
Pathology: cancer cells compress intratumour vessels. Nature (2004) 3.60
Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology (2005) 3.51
Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology (2008) 3.47
Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev (2005) 3.38
RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer (2006) 3.15
Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol (2001) 3.09
Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer (2006) 3.06
Microvascular permeability of normal and neoplastic tissues. Microvasc Res (1986) 3.04
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol (2009) 3.02
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res (2009) 3.00
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res (2013) 2.98
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
Microscopic susceptibility variation and transverse relaxation: theory and experiment. Magn Reson Med (1994) 2.79
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst (2004) 2.79
Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell (2012) 2.76
MR contrast due to microscopically heterogeneous magnetic susceptibility: numerical simulations and applications to cerebral physiology. Magn Reson Med (1991) 2.75
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A (2012) 2.66
Quantitative BOLD: mapping of human cerebral deoxygenated blood volume and oxygen extraction fraction: default state. Magn Reson Med (2007) 2.55
Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation (2010) 2.53
Intravascular susceptibility contrast mechanisms in tissues. Magn Reson Med (1994) 2.48
Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res (2005) 2.44
Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab (2009) 2.43
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res (2011) 2.40
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun (2013) 2.31
Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. AJNR Am J Neuroradiol (2004) 2.27
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A (2013) 2.14
End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol (2009) 2.13
Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology (2006) 2.10
NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med (1998) 2.08
Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application. Quant Imaging Med Surg (2011) 2.07
Technology insight: water diffusion MRI--a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol (2008) 2.03
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol (2012) 2.01
Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer (2009) 2.00
Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med (2000) 1.94
Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res (2013) 1.87
Measurement of MRI scanner performance with the ADNI phantom. Med Phys (2009) 1.85
Accuracy of gamma-variate fits to concentration-time curves from dynamic susceptibility-contrast enhanced MRI: influence of time resolution, maximal signal drop and signal-to-noise. Magn Reson Imaging (1997) 1.79
The roles of cerebral blood flow, capillary transit time heterogeneity, and oxygen tension in brain oxygenation and metabolism. J Cereb Blood Flow Metab (2011) 1.76
Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Mol Interv (2004) 1.74
Vessel size imaging. Magn Reson Med (2001) 1.70
Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol (2012) 1.69
Contrast agents and cerebral hemodynamics. Magn Reson Med (1991) 1.55
Strategies for advancing cancer nanomedicine. Nat Mater (2013) 1.48
Changes in human cerebral blood flow and cerebral blood volume during hypercapnia and hypocapnia measured by positron emission tomography. J Cereb Blood Flow Metab (2003) 1.47
Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med (2013) 1.46
Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist (2004) 1.45
Changes in the arterial fraction of human cerebral blood volume during hypercapnia and hypocapnia measured by positron emission tomography. J Cereb Blood Flow Metab (2005) 1.39
Theoretical basis of hemodynamic MR imaging techniques to measure cerebral blood volume, cerebral blood flow, and permeability. AJNR Am J Neuroradiol (2007) 1.39
Vessel size imaging in humans. Magn Reson Med (2005) 1.37
Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst (2000) 1.36
Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal in vivo and ex vivo study. NMR Biomed (2008) 1.35
Spin-echo and gradient-echo EPI of human brain activation using BOLD contrast: a comparative study at 1.5 T. NMR Biomed (1994) 1.29
Quantitative imaging biomarkers in neuro-oncology. Nat Rev Clin Oncol (2009) 1.28
When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst (2012) 1.28
Susceptibility contrast imaging of cerebral blood volume: human experience. Magn Reson Med (1991) 1.26
A novel technique for modeling susceptibility-based contrast mechanisms for arbitrary microvascular geometries: the finite perturber method. Neuroimage (2008) 1.25
Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. Neuro Oncol (2003) 1.25
Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review. J Biomed Biotechnol (2011) 1.25
Analytical model of susceptibility-induced MR signal dephasing: effect of diffusion in a microvascular network. Magn Reson Med (1999) 1.24
MR imaging of microvasculature. Magn Reson Med (2000) 1.23
Benefits of vascular normalization are dose and time dependent--letter. Cancer Res (2013) 1.22
In vivo assessment of tumoral angiogenesis. Magn Reson Med (2004) 1.22
Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imaging (2009) 1.15